A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients.

Trial Profile

A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs AFP 464 (Primary)
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2010 Status changed from not yet recruiting to withdrawn prior to recruitment.
    • 28 Sep 2010 This muticentre trial is expected to be initiated in 2010 according to a Tigris Pharmaceuticals media release.
    • 23 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top